用于预测多发性骨髓瘤预后、免疫浸润和化疗反应的新的铁突变相关lncRNA风险特征。

IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Discover. Oncology Pub Date : 2025-02-11 DOI:10.1007/s12672-025-01947-z
Wei Yu, Zizi Jing, Jialin Tang, Jianbin Chen
{"title":"用于预测多发性骨髓瘤预后、免疫浸润和化疗反应的新的铁突变相关lncRNA风险特征。","authors":"Wei Yu, Zizi Jing, Jialin Tang, Jianbin Chen","doi":"10.1007/s12672-025-01947-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis, an iron-dependent form of programmed cell death, has been implicated in various types of cancer. However, the association between ferroptosis-related long noncoding RNAs (FRLs) and multiple myeloma (MM) remains unclear. This study aimed to develop an FRL-based predictive model to assess its potential role in predicting overall survival prognosis and evaluating immune cell infiltration and chemotherapy response in MM patients.</p><p><strong>Methods: </strong>We identified FRLs using the GEO and FerrDb databases and employed univariate Cox regression and least absolute shrinkage and selection operator (LASSO) to establish a prognostic FRLs signature in the training cohort. The reliability of the risk model was evaluated using Kaplan-Meier (K-M) and time-dependent receiver operating characteristic (ROC) curve analyses. Gene set enrichment analysis (GSEA) was conducted to explore the biological functions associated with the FRLs signature. We also assessed immune cell infiltration and estimated the IC50 of drugs using the R package 'pRRophetic'. The expression of FRLs was validated by qRT-PCR.</p><p><strong>Results: </strong>We established a novel 8 FRLs signature, comprising AC005592.1, AC093714.1, AC104041.1, AL122058.1, DIRC1, ERVH-1, FAM223B, and TDRKH-AS1. The risk model was identified as an independent risk factor for overall survival (OS) in MM patients. Bioinformatics analysis indicated that the high-risk group exhibited activation of carcinogenic signaling pathways and immune cell infiltration. The qRT-PCR confirmed the significant upregulation in the expression of ERVH-1, TDRKH-AS1, and AC104041.1, and the downregulation of DIRC1, AC005592.1, AC093714.1, and AL122058.1 in MM samples. Furthermore, the ferroptosis inducer erastin triggered ferroptosis, inhibited cell viability, and upregulated TDRKH-AS1.</p><p><strong>Conclusion: </strong>Our study highlights the potential of the FRLs signature as a prognostic tool and its implications for therapeutic strategies in MM.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"160"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813854/pdf/","citationCount":"0","resultStr":"{\"title\":\"A novel defined risk signature of ferroptosis-related lncRNAs for predicting prognosis, immune infiltration, and chemotherapy response in multiple myeloma.\",\"authors\":\"Wei Yu, Zizi Jing, Jialin Tang, Jianbin Chen\",\"doi\":\"10.1007/s12672-025-01947-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ferroptosis, an iron-dependent form of programmed cell death, has been implicated in various types of cancer. However, the association between ferroptosis-related long noncoding RNAs (FRLs) and multiple myeloma (MM) remains unclear. This study aimed to develop an FRL-based predictive model to assess its potential role in predicting overall survival prognosis and evaluating immune cell infiltration and chemotherapy response in MM patients.</p><p><strong>Methods: </strong>We identified FRLs using the GEO and FerrDb databases and employed univariate Cox regression and least absolute shrinkage and selection operator (LASSO) to establish a prognostic FRLs signature in the training cohort. The reliability of the risk model was evaluated using Kaplan-Meier (K-M) and time-dependent receiver operating characteristic (ROC) curve analyses. Gene set enrichment analysis (GSEA) was conducted to explore the biological functions associated with the FRLs signature. We also assessed immune cell infiltration and estimated the IC50 of drugs using the R package 'pRRophetic'. The expression of FRLs was validated by qRT-PCR.</p><p><strong>Results: </strong>We established a novel 8 FRLs signature, comprising AC005592.1, AC093714.1, AC104041.1, AL122058.1, DIRC1, ERVH-1, FAM223B, and TDRKH-AS1. The risk model was identified as an independent risk factor for overall survival (OS) in MM patients. Bioinformatics analysis indicated that the high-risk group exhibited activation of carcinogenic signaling pathways and immune cell infiltration. The qRT-PCR confirmed the significant upregulation in the expression of ERVH-1, TDRKH-AS1, and AC104041.1, and the downregulation of DIRC1, AC005592.1, AC093714.1, and AL122058.1 in MM samples. Furthermore, the ferroptosis inducer erastin triggered ferroptosis, inhibited cell viability, and upregulated TDRKH-AS1.</p><p><strong>Conclusion: </strong>Our study highlights the potential of the FRLs signature as a prognostic tool and its implications for therapeutic strategies in MM.</p>\",\"PeriodicalId\":11148,\"journal\":{\"name\":\"Discover. Oncology\",\"volume\":\"16 1\",\"pages\":\"160\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-02-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813854/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Discover. Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12672-025-01947-z\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-01947-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:铁凋亡是一种依赖铁的程序性细胞死亡形式,与多种类型的癌症有关。然而,与铁凋亡相关的长链非编码rna (frl)与多发性骨髓瘤(MM)之间的关系尚不清楚。本研究旨在建立一种基于frl的预测模型,以评估其在预测MM患者总生存预后和评估免疫细胞浸润和化疗反应中的潜在作用。方法:我们使用GEO和FerrDb数据库确定frl,并使用单变量Cox回归和最小绝对收缩和选择算子(LASSO)在训练队列中建立预后frl签名。采用Kaplan-Meier (K-M)和随时间变化的受试者工作特征(ROC)曲线分析评估风险模型的可靠性。通过基因集富集分析(GSEA)来探索与frl特征相关的生物学功能。我们还评估了免疫细胞浸润,并估计了使用R包装的药物的IC50。qRT-PCR验证frl的表达。结果:我们建立了一个新的8个frl签名,包括AC005592.1、AC093714.1、AC104041.1、AL122058.1、DIRC1、ERVH-1、FAM223B和TDRKH-AS1。风险模型被确定为MM患者总生存(OS)的独立危险因素。生物信息学分析表明,高危组表现出致癌信号通路激活和免疫细胞浸润。qRT-PCR证实,MM样品中ERVH-1、TDRKH-AS1、AC104041.1的表达显著上调,DIRC1、AC005592.1、AC093714.1、AL122058.1的表达下调。此外,铁下垂诱导剂erastin触发铁下垂,抑制细胞活力,上调TDRKH-AS1。结论:我们的研究强调了frl特征作为预后工具的潜力及其对MM治疗策略的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A novel defined risk signature of ferroptosis-related lncRNAs for predicting prognosis, immune infiltration, and chemotherapy response in multiple myeloma.

Background: Ferroptosis, an iron-dependent form of programmed cell death, has been implicated in various types of cancer. However, the association between ferroptosis-related long noncoding RNAs (FRLs) and multiple myeloma (MM) remains unclear. This study aimed to develop an FRL-based predictive model to assess its potential role in predicting overall survival prognosis and evaluating immune cell infiltration and chemotherapy response in MM patients.

Methods: We identified FRLs using the GEO and FerrDb databases and employed univariate Cox regression and least absolute shrinkage and selection operator (LASSO) to establish a prognostic FRLs signature in the training cohort. The reliability of the risk model was evaluated using Kaplan-Meier (K-M) and time-dependent receiver operating characteristic (ROC) curve analyses. Gene set enrichment analysis (GSEA) was conducted to explore the biological functions associated with the FRLs signature. We also assessed immune cell infiltration and estimated the IC50 of drugs using the R package 'pRRophetic'. The expression of FRLs was validated by qRT-PCR.

Results: We established a novel 8 FRLs signature, comprising AC005592.1, AC093714.1, AC104041.1, AL122058.1, DIRC1, ERVH-1, FAM223B, and TDRKH-AS1. The risk model was identified as an independent risk factor for overall survival (OS) in MM patients. Bioinformatics analysis indicated that the high-risk group exhibited activation of carcinogenic signaling pathways and immune cell infiltration. The qRT-PCR confirmed the significant upregulation in the expression of ERVH-1, TDRKH-AS1, and AC104041.1, and the downregulation of DIRC1, AC005592.1, AC093714.1, and AL122058.1 in MM samples. Furthermore, the ferroptosis inducer erastin triggered ferroptosis, inhibited cell viability, and upregulated TDRKH-AS1.

Conclusion: Our study highlights the potential of the FRLs signature as a prognostic tool and its implications for therapeutic strategies in MM.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Discover. Oncology
Discover. Oncology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.40
自引率
9.10%
发文量
122
审稿时长
5 weeks
期刊最新文献
A case of breast acinar cell carcinoma combined with metaplastic carcinoma. A nomogram model based on dual-center data predicts lymph node metastasis in endometrial cancer. Overexpression of MFAP4 inhibits the proliferation, migration, and invasion of bladder cancer cells. Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast. Recent advances in lipid and biomimetic nanocarriers for nucleic acid delivery in glioblastoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1